retatrutide fda approval status eli lilly approves this year? Predictions & Odds 2026 Eli Lilly gave mysterious access

This is why kidney protection has become a major focus of diabetes care worldwide

Honestly, the 50% off deal for the first month of Semaglutide was a big draw

Finding the right dose is a matter of balancing stronger effects against tolerability

Retatrutide for type 2 diabetes: Phase 2 trial results (36-week study, HbA1c reductions, weight loss) New England Journal of Medicine (2023) Jastreboff AM, et al

Quick Stats for Obesity GLP-1 Market Obesity GLP-1 Market Value (2025): USD 8,169 million Obesity GLP-1 Market Forecast Value (2035): USD 65,364 million Obesity GLP-1 Market Forecast CAGR: 23.1% Leading Molecule Class in Obesity GLP-1 Market: Semaglutide (58.0%) Key Growth Regions in Obesity GLP-1 Market: North America, Europe, and East Asia Top Key Players in Obesity GLP-1 Market: Novo Nordisk, Eli Lilly, and emerging manufacturers Between 2025 and 2030, the obesity GLP-1 market is projected to expand from USD 8169.0 million to USD 39,528 million, resulting in a value increase of USD 31359.0 million, which represents 54.8% of the total forecast growth for the decade